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Abstract: Prion diseases are rare transmissible neurodegenerative disorders caused by the accumulation
of a misfolded isoform (PrPSc) of the cellular prion protein (PrPC) in the central nervous system
(CNS). Neuropathological hallmarks of prion diseases are neuronal loss, astrogliosis, and enhanced
microglial proliferation and activation. As immune cells of the CNS, microglia participate both in
the maintenance of the normal brain physiology and in driving the neuroinflammatory response to
acute or chronic (e.g., neurodegenerative disorders) insults. Microglia involvement in prion diseases,
however, is far from being clearly understood. During this review, we summarize and discuss
controversial findings, both in patient and animal models, suggesting a neuroprotective role of
microglia in prion disease pathogenesis and progression, or—conversely—a microglia-mediated
exacerbation of neurotoxicity in later stages of disease. We also will consider the active participation
of PrPC in microglial functions, by discussing previous reports, but also by presenting unpublished
results that support a role for PrPC in cytokine secretion by activated primary microglia.
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1. Introduction—The Prion Protein, Prions and Prion Diseases
The cellular prion protein, PrPC, is a glycosylphosphatidylinositol (GPI)-anchored protein, residing
in the outer leaflet of the plasma membrane (PM), expressed in several cell types and particularly
abundant in the central nervous system (CNS) and immune cells [1].
PrPC is primarily renowned for being the precursor of prions, the proteinaceous infectious agents
lacking nucleic acids that cause invariably fatal neurodegenerative disorders named transmissible
spongiform encephalopathies (TSEs) or prion diseases in humans and other mammalian species [2–4].
Prion diseases are rare disorders, affecting about one or two people per million per year world-wide,
nevertheless they attract remarkable attention due to the unique biology of the transmissible agent.
Prions form upon the conversion of PrPC into an insoluble, protease-resistant conformer (PrPSc) that is
the major, if not unique, component of the infectious particle. Although all TSEs share the presence
of PrPSc aggregate deposition, they present with a variety of etiological and neuropathological traits,
affecting different CNS areas, and causing various clinical manifestations.
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The great majority of human prion diseases arise sporadically (e.g., sporadic Creutzfeldt–Jakob disease
(CJD)), but a significant percentage (~10%) is of genetic origin, due to the autosomal dominant transmission
of inherited mutations in the PrPC-coding gene (e.g., genetic CJD, Gerstmann–Sträussler–Scheinker
syndrome and fatal familial insomnia) and about 5% of all cases develop on infectious grounds
(e.g., Kuru, iatrogenic CJD and a new variant form of CJD that was transmitted to humans through the
consumption of meat from bovine spongiform encephalopathy-affected cattle) [5].
The classical diagnostic triad of TSEs comprises spongiform vacuolation of the cerebral grey
matter, neuronal loss, and chronic neuroinflammation [6]. Regarding the latter aspect, activation and
proliferation of microglia and astrocytes have been recognized as obligatory features of the disease,
regardless of the TSE form (reviewed in [7–9]). However, the determination of the precise role of glia
in prion diseases and other neurodegenerative diseases, which are commonly associated with chronic
neuroinflammation, is still a matter of debate [10–14]. Taking this context, it is worth remarking that
the cellular mechanisms leading to brain damage in TSEs are far from being understood, and it is
not yet clear if they rely on a gain in the toxicity of PrPSc aggregates or a loss of function of PrPC
(due to its continuous conversion into PrPSc), or both. Concerning the loss of function hypothesis,
the understanding of PrPC physiological function would be of paramount importance. While both
the high evolutionary conservation and the almost ubiquitous expression of PrPC would suggest
fundamental roles for the protein, and in spite of decades of extensive research, a comprehensive view
of PrPC function, however, is still missing.
The possible involvement of PrPC in microglia pathophysiology and the role of microglia in PrPSc
infection and propagation during prion disease are the major topic of this review. Particularly, we will
discuss previous controversial results on the role of PrPC on microglial activation and cytokine release,
and also provide our unpublished data.
2. Microglia Function in Health and Prion Diseases
2.1. Microglia Origin and Function in the Healthy Brain
Microglia belong to the glial system of non-neuronal cells and represent the resident immune
population of the CNS. Although it has been studied for decades, the developmental origin of microglia
remained debated for a long time [15]. Recent studies confirmed the prediction of the founder
of the microglia field, Pio del Rio–Hortega [16], indicating that microglial cells are derived from
c-Kit+ erythromyeloid precursors in the yolk sac that seed the CNS rudiment from the cephalic
mesenchyme very early during embryogenesis and continuing until the blood–brain barrier is formed,
following a gradual process of differentiation into highly specialized immune cells in the brain [17,18].
After such a developmental origin, self-renewal is the only source of new microglial cells in the healthy
brain, which is regulated also by astrocytes and neurons through the activation of the microglial
colony-stimulating factor (CSF)-1 tyrosine kinase receptor (CSF-1R) by its ligands CSF-1 and interleukin
(IL)-34 [19].
Microglial cells play a key role in the maintenance of brain homeostasis from early development
to adulthood, including neurodevelopment, synaptic pruning, neuronal circuit maturation [20,21],
and the impairment of microglial functions which can lead to severe pathological outcomes.
Under healthy conditions, microglial cells are characterized by a small cell soma and numerous
branching processes involved in the clearance of metabolic products and apoptotic cells or cell
debris [22]. Key surface receptors (i.e., cluster of differentiation (CD) 45, CD14, and CD11b/CD18
(Macrophage-1 antigen)) maintain microglial cells in a resting but highly dynamic state [23] that is
favored by the interaction with neurons, for example through the formation of a molecular complex
between the neuronal transmembrane glycoprotein CD200 and its receptor CD200R present in the
plasma membrane of microglial cells [24], or between the neuronal chemokine C-X3-C motif chemokine
(CX3C) ligand 1 (CX3CL1, also named Fractalkine) and its receptor CX3CR1, expressed solely by
microglial cells [25].
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2.2. Microglia Involvement in Neuropathology
Under pathological circumstances, such as brain injury, microbial infection, or neurodegeneration,
microglial activation leads to morphological changes, up-regulation of surface receptors, secretion of a
multitude of cytokines, chemokines, and reactive oxygen species (ROS) [26], and the acquisition of a
phagocytic phenotype [27]. Most in vitro and in vivo studies used the bacterial cell wall endotoxin
lipopolysaccharide (LPS) (reviewed in [28–30]) or pro-inflammatory cytokines (e.g., interferon-γ (IFNγ)
and tumor necrosis factor-α (TNF-α)) to achieve microglial activation [31].
Activated microglia could exist in a range of activation states that span from two opposite
phenotypes, the pro-inflammatory (M1) and the anti-inflammatory (M2) phenotype, with the phenotype
of activated microglia falling somewhere along this spectrum, depending on incoming signals. A precise
balance between M1 and M2 is of paramount importance for the resolution of inflammation. Indeed,
the M1 phase is characterized by the secretion of pro-inflammatory mediators, such as TNF-α, IL-1β,
IL-6, nitric oxide (NO), ROS, chemokines (e.g., macrophage inflammatory protein 1α, monocyte
chemoattractant protein-1 (MCP-1) and the IFN inducible protein 10) and neurotoxins. When such
a strong pro-inflammatory response protracts over time (e.g., under chronic conditions such as
neurodegenerative disorders), the sustained release of inflammatory mediators and oxidative and
nitrosative stress may exacerbate neuronal damage [13,32,33], a circumstance that may well occur in
prion diseases (see below, [9]). Conversely, in the M2 response, microglia exert numerous beneficial
effects through the release of anti-inflammatory factors (e.g., IL-4, IL-10, transforming growth factor-β
(TGF-β), insulin-like growth factor 1 and brain-derived neurotrophic factor) [34,35], protecting against
brain damage.
2.3. Microglial Proliferation/Activation in Prion Diseases
An active involvement of microglial activation and cytokine signaling in prion diseases has
been suggested by a wealth of observations reporting different microglial responses in human
CJD [36,37], in bovine spongiform encephalopathies [38], in scrapie [39], in animal models of the
diseases (i.e., rodents [40–42] or sheep [43] infected with experimental prion strains, or prion mimetics,
see below) and in cultured microglial cells exposed to PrPSc [40,44].
Both in patient and in animal models of prion diseases, PrPSc aggregates have been found
inside and around microglial cells, inducing activation that correlates temporally with the onset and
development of clinical and molecular signs of the disease [40,45–53].
The huge experimental effort, however, failed to precisely define the microglial role in prion disease
progression (for a comprehensive review, see [7]). It is well-accepted, on one hand, that microglial activation
begins in the early stages of disease, preceding neuronal loss and spongiform neurodegeneration,
which would suggest that microglial activation is a cause rather than a consequence of neuronal demise
(reviewed in [9]). A wealth of evidence, on the other hand, supports the hypothesis that microglia play
a neuroprotective role in prion disease-related neuronal damage [7].
One of the most exploited models for studying prion diseases is that involving the use of mice
infected with different prion strains, which recapitulated most pathological features of TSEs. Using this
experimental setting, the involvement of microglia in prion diseases was principally investigated
in mice in which microglial activation and cytokine signalling was altered either genetically or
pharmacologically [54–56].
Probably due to the variety of the experimental paradigms, however, such approaches provided
conflicting conclusions on the role of microglia in prion disease pathogenesis, as discussed below.
Some studies showed a beneficial role of microglia activation in prion diseases. They demonstrated,
for example, that Toll-like receptors (TLRs) are involved in prion-induced microglial activation,
exploiting a protective function during disease pathogenesis [7] and suggesting that TLR signalling
controls the progression of prion disease, as also indicated by the finding that a loss-of-function
mutation in TLR4 decreased survival after prion infection [57].
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Conversely, however, it also has been suggested that the chronic activation of microglia might have
a detrimental effect in the defence against prions. Particularly, a key role in the sustained maintenance of
activated microglia in prion disease is retained by the CSF-1R signalling pathway. Indeed, a reduction
of proliferating microglia was observed in PrPSc-infected mice treated with the selective inhibitor of
CSF-1R, GW2580, with a consequent slowdown in neuronal damage and disease progression [56].
Furthermore, the expression of the microglial GPI-anchored protein CD14, a TLR co-receptor
involved in microglia activation, significantly increases in mice infected with different prion strains,
as demonstrated by large-scale transcriptomic studies [58,59]. Interestingly, PrPSc-infected CD14
knock-out (KO) mice survived longer and expressed more anti-inflammatory cytokines (such as IL-10
and TGF-β [54], IL-13 [60]) and less pro-inflammatory IL-1β than PrPSc-infected wild-type (WT)
mice [54], suggesting a harmful role for CD14-mediated signalling in prion pathogenesis (Figure 1).
Figure 1. The GPI-anchored cell surface TLR co-receptor CD14 is upregulated in microglial cells during
prion infection, while CD14 genetic deletion blocks (T-arrow) CD14 upregulation and prolongs survival
in prion infected knock-out mice (red × symbol).
Another key issue is the involvement of astroglial cells in prion replication, and propagation
to neighboring cells (i.e., neurons) and throughout the CNS, which has been proposed to occur in
prion diseases [34,61] and other neurodegenerative disorders associated with prion-like proteins [62].
While the direct participation of astrocytes and neurons in PrPSc replication and spread is well
recognized [43,63–69], the role of microglia in such processes is still debated [34]. The low basal
levels of PrPC in microglia may suggest that these cells unlikely support the PrPC-to-PrPSc transition
and act as foci of prion propagation. Nonetheless, the increase of PrPC levels in microglia under
inflammatory conditions, such as those occurring during prion infection or—experimentally—upon
microglia activation by LPS (see below), may enhance the capability of microglial cells to favor prion
replication and spreading [42,70].
Taking this context, it also is worth noting that in other neurodegenerative proteinopathies, sharing
with prion diseases the molecular mechanisms of propagation of aberrant protein conformers [71,72],
the contribution of microglia in cell-to-cell transmission of proteinaceous neuropathogens has been
proposed. As examples, this is the case for α-synuclein in Parkinson’s disease models [73], and of the
tau protein in Alzheimer’s disease-related tauopathies [74–76].
2.4. Cytokines/Chemokines Signalling Alteration in Prion Diseases
Another important and widely studied issue related to microglial response in prion
diseases concerns the role of cytokines and chemokines. As previously described, both pro- and
anti-inflammatory cytokines are increased in the CNS in response to prion infection. These molecules
are produced by activated microglia and astrocytes, since leukocytes from the periphery do not infiltrate
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the CNS in prion diseases [9], and exert different functions in the inflammatory response to brain injury,
as described above.
Regarding whole brain or isolated microglial cells of PrPSc-infected mice, an upregulation of
anti-inflammatory cytokines and chemokines (principally in the early stages of prion infection) [10,41,77],
or of pro-inflammatory ones [78–87] have been observed. The different results obtained in such studies
may be attributable to several factors, including the used prion strains, the stage of disease, different
mouse genetic backgrounds, or techniques applied for the analyte detection.
Among the pro-inflammatory cytokines, IL-1 seems to play a prominent detrimental role in
prion-associated neuroinflammation, since knocking-out the IL-1 receptor 1 (IL-1R1) prolongs prion
incubation times and delays disease progression in scrapie infected IL-1R1 KO [88,89].
The role of anti-inflammatory cytokines in prion diseases mainly has been investigated by means
of IL-4, IL-10, and IL-13 KO mice. Among these cytokines, the only one playing a protective role in
prion diseases is IL-10, as suggested by the finding that prion-inoculated IL-10 KO mice have a faster
onset and progression of the disease. IL-10 absence also favors TNF-α expression, thereby promoting a
sustained pro-inflammatory response [90]. However, conflicting results were obtained in IL-10 KO
mice with a different genetic backgrounds [89], supporting the idea that the IL-10-neuroprotective
effect is strongly dependent on the genetic context (Figure 2).
Figure 2. Exposure to PrPSc or prion mimetics (e.g., the fibrillogenic 106-126 peptide) activates microglial
cells promoting the secretion of either pro-inflammatory IL-1 (resulting in enhanced neurodegenerative
cues), or anti-inflammatory IL-10 (exerting neuroprotective effects).
Also, numerous chemokines (e.g., MCP-1, Regulated upon Activation, Normal T cell Expressed,
and Secreted (RANTES), C-X-C motif ligand (CXCL)3, CXCL9, CXCL10) and chemokine receptors
(CCR) (e.g., CCR1, CCR5 and CCR3) are up-regulated in prion diseases, but their role in the pathology
remains unclear since different studies provided conflicting results [7]. Signalling pathways activated
by CXCL9 and CXCL10 seem to directly contribute to prion disease progression, as suggested by the
finding that scrapie infected-CXCR3 KO mice (lacking the CXCL9 and CXCL10 receptor), although
exhibiting exacerbated astrocytosis and accelerated accumulation of PrPSc, showed reduced microglia
activation and pro-inflammatory factor secretions, and survived longer compared to scrapie-infected
WT mice [91]. To contrast, prion infected-CCR1 KO mice (lacking the RANTES receptor) showed a
worsened prion disease course and a lower survival rate with respect to infected WT mice [92].
Considering this, animal models provided conflicting results also for the involvement of the
CX3CL1/CX3CR1 signalling axis in prion neuropathology. While Grizenkova et al., [55] suggested
that CX3CR1 (a receptor for the CX3CL1 chemokine) activation is neuroprotective, a subsequent study
demonstrated no contribution of the receptor to disease progression [93].
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2.5. Microglial Activation by the Prion Mimetic PrP106-126 Neurotoxic Peptide
Considering the above reported controversial results provided by animal models, it is worth
discussing a simpler experimental model that has been widely employed to study the microglia
contribution to prion-related neurodegenerative processes. We specifically refer to the use of the
fibrillogenic and neurotoxic peptide 106-126 derived from the human prion protein sequence
(PrP106-126) [94], characterized by its intrinsic capability to form fibrils in vitro [95] and to induce a
PrP-dependent neuronal cell death [96] by the activation of apoptotic cell death pathways [97].
Interestingly, the PrP106-126 neurotoxic effect requires the presence of microglia [98] and was
demonstrated to be independent from de novo generation of PrPSc [99].
Particularly the PrP106-126 peptide, or other longer peptides containing the PrP106-126 sequence,
induced the activation and proliferation of immortalized microglial cells [100–102] and primary microglia
cultures [103–111], and stimulated astroglial proliferation [112,113]. Furthermore, such fibrillogenic
peptides induced the secretion of different pro-inflammatory cytokines (i.e., TNF-α, [105]; RANTES,
Granulocyte-CSF, and IL-12, [100]; IL-1β, IL-6, [104,106]), and caused an increase of NO synthase and
NO release that appears to be essential for the mediation of neurotoxicity [98,105], as demonstrated
by the neuronal death induced in neurons co-cultured with microglia treated with the PrP106-126
peptide [106] (Figure 2).
Taken together, the above summarized findings—based on the use of PrP-derived
peptides—support the contention that microglial cells contribute to prion-related neurodegenerative
processes by producing pro-inflammatory cytokines and oxidative stress, which are recognized as
mediators of neuronal death. Nonetheless, it is worth underlining that some doubts on the relevance
and validity of results obtained with prion protein-derived peptides were forwarded, since such
studies often disregarded the non-infectious nature of PrP106-126, its absence in clinical cases, or its
spontaneous production in in vivo experimental settings [7].
3. A possible Role for PrPC in Neuroinflammation
Until now, we have presented and discussed previous studies aimed at relating microglia activation
and cytokine signalling in prion neuropathology in animal and cell models challenged with prions or
prion surrogates. However, in line with the loss-of-function hypothesis in prion diseases, it also is
plausible to consider that PrPC-to-PrPSc conversion and the consequent irreversible recruitment of the
protein into newly formed prions may severely perturb physiologic PrPC functions in microglia and/or
microglia-neuron crosstalk. The most reliable and exploited model for investigating such a hypothesis
is the use of PrP-KO mice.
Although no phenotypic disturbances were originally recognized in PrP-KO mice [114,115], further
investigation revealed numerous subtle phenotypes in different PrPC-deficient mice, many of which
were exacerbated upon stressful conditions [116,117]. These models suggested pleiotropic functions
for PrPC [1,116], among which was the involvement in the inflammatory response both in the CNS and
peripheral extra-neural tissues [118–124]. The protective role of PrPC in the inflammatory response also
was suggested by the higher expression of the protein in the so-called immuno-privileged sites, such as
the CNS, eyes, placenta, fetus and testicles [125]. Despite controversial data, it is conceivable that PrPC
is involved also in the regulation of phagocytosis, a fundamental process for both the resolution of
inflammation and the immune response against pathogens [126–129].
Interestingly, PrPC seems to regulate the expression and/or the secretion of pro- or anti-inflammatory
cytokines after systemic LPS administration in vivo, although the involved signalling pathways and
mechanisms are largely unknown [121,123,124,130]. Recently, a new scenario emerged demonstrating
that PrPC increases TNF-α production through the stimulation of pro-TNF-α cleavage (as demonstrated
in serotoninergic neurons [131] and muscle cells [132]) by the activation of the TNF-α converting
enzyme (TACE), a member of the A-Disintegrin-and-Metalloproteinase family, via its coupling to
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Alternately, by activating the same
NADPH oxidase-TACE axis and by modulating TACE localization in the plasma membrane, PrPC also
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may promote the shedding of transmembrane TNF-α receptors, thereby protecting against excessive
pro-inflammatory TNF-α response [133].
Unfortunately, even such studies aimed at elucidating PrPC function in microglial cells using
PrP-KO models provided contradictory data. Indeed, while early studies on immortalized microglial
cells suggested a key role for PrPC in microglial activation and regulation of the inflammatory
response [134,135], more recent data, obtained in murine primary microglial cultures stimulated with
LPS, reported no difference in cell morphology, microglial marker expressions and cytokine production
between cells expression, or not, PrPC [136].
Viewing this puzzling context, we analyzed the influence of PrPC in microglial function and
cytokine production using a mouse model with a different genetic background with respect to those
previously employed. Starting from cortical microglial primary cultures from 2–3 post-natal day
transgenic (Tg) mice expressing (PrP-Tg) or not PrPC (PrP-KO), we induced microglia activation
by adding LPS to the culture medium. Interestingly, LPS-treated (for 96 h) PrP-Tg microglial cells
expressed higher PrPC amounts compared to non-treated cells (Figure 3A), as already observed in
other cell models [130,137,138]. This result corroborated the hypothesis of a key role of PrPC in the
microglial activation process.
Using the same experimental setting, we evaluated the secretion of pro- (IL-1β, IFN-γ, IL-6, TNF-α)
and anti-inflammatory (IL-10) cytokines at 24 h and 96 h after LPS-activation of microglia expression,
or not, PrPC. We chose this restricted set of cytokines because they were found to be de-regulated in
CJD patients and prion infected mice [7], suggesting their involvement in prion neuropathology.
Shown in Figure 3B, our results demonstrated that, in our experimental paradigm (PrP-KO and
PrP-expressing mice with an almost pure FVB genetic background, [139]), the secretion of both pro-
and anti-inflammatory cytokines was higher in PrP-expressing microglia after 24 h of LPS treatment,
while after prolonged inflammatory stimulus, only pro-inflammatory cytokine (IL-1β, IFN-γ, IL-6,
and TNF-α) release was stimulated by the presence of PrPC (for experimental details, see the legend to
Figure 3).
Such findings are in agreement with previous data obtained from immortalized microglia-like
cell line, expressing or not PrPC, in which it was shown that PrPC expression alters TNF-α and
IL-1β [134,135] or TGF-β and IL-10 [134] secretion. However, our results are in contrast with data
obtained by Pinheiro et al., [136], reporting that genetic ablation of PrPC did not affect LPS-induced
production of pro-inflammatory (TNF-α, IL-6, IL-1β) and anti-inflammatory (IL-10) cytokines.
We conceive that the discrepancy between our observations and the previously reported results
may originate from the different genetic background of the mouse models (FVB, our experiments;
B10.129Ola, Pinheiro and co-workers). It has been suggested, for example, that a polymorphism in the
SIRPA gene, encoding the signal regulatory protein (Sirp) α, can be responsible for many phenotypes
often associated to PrPC ablation in different mouse genetic backgrounds [140]. To the best of our
knowledge, however, the SIRPA genotype was never analysed in the PrP-KO FVB strain that we have
employed in our studies, thus further investigation is needed to understand the possible role of Sirpα,
or a Sirpα-PrPC cross-talk, in microglial activation and cytokine production.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 8 of 16 
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cultured for 96 h in the absence (–) or in the presence (+) of lipopolysaccharide (LPS) (500 ng/mL), 
then cells were lysed, and extracted proteins were subjected to Western blot (WB), as described 
previously [142]. The left panel shows a representative WB, out of three biological replicates (i.e., 
different primary cell cultures), using a mouse monoclonal antibody to PrPC (clone 8H4, Abcam). A 
mouse monoclonal anti-α-Tubulin antibody (clone B-5-1-2, Sigma–Aldrich) also was used to check 
for the loading of equal protein amounts. The right panel reports the densitometric analysis of PrPC 
immuno-reactive bands in control (–) or LPS-treated cells (+), normalized to the corresponding signal 
of α-Tubulin. Data were then normalized to PrPC amounts in control cells. Data show that LPS 
addition significantly increases PrPC expression levels in PrP-Tg-derived microglial cells. As expected, 
no PrPC reactive band was observed in PrP-KO samples, confirming the specificity of the 
immunosignal. Values are expressed as mean ± standard error of the mean (SEM), n = 3. Statistical 
analysis was based on unpaired two-tailed Student’s t-test. ** p-value < 0.01. (B) PrPC regulates the 
production of cytokines by primary murine microglial cells upon LPS treatment. Microglial cells (as 
in panel A) were maintained in culture in the presence of LPS (500 ng/mL) for 24 h or 96 h. The 
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assays were performed in 96-well filter plates by Multiplexed Luminex®-based immunoassay, as 
previously described [143], following the manufacturer’s instructions, and analyzed in the BioPlex 
200 instrument (BioRad). The table reports the cytokine amounts (estimated from a standard curve 
using a fifth-order polynomial equation and adjusted for the dilution factor), normalized to the total 
protein content (determined by a Lowry assay kit (Sigma-Aldrich)) in the corresponding cell lysates 
and then subtracted for the values obtained in the absence of LPS. Values are expressed as mean ± 
SEM, n = 5 (biological cultures for each genotype). Statistical analysis was based on unpaired two-
tailed Student’s t-test. * p-value < 0.05.  
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at UC , London, UK. Cel cultures w re established and m i taine as described previously [141].
All procedures wer pe formed in compliance with European and Italian (D.L. 26/2014) laws concerni
t f laboratory animals and were ap roved by the Itali n Ministry of Health, and by the
Ethical Committee of the University of Pad va (Authoriza ion n. 743/2017-PR). Cells were cultured
for 96 h in the absence (–) or in the presenc (+) of lipopolysaccharide (LPS) (500 ng/mL), then cells
w re lysed, and extracted proteins were subjected to Western blot ( B), as described previously [142].
The left panel shows a representative WB, out of three biological replicat s (i.e., different primary c ll
cultures), using a mouse monoclo al antibody t PrPC (clo e 8H4, Abcam). A mouse monoclonal
anti-α-Tubulin antibody (clone B-5-1-2, Sigma–Aldrich) also was used to check for the loading of
equal protei amounts. The right panel reports the de sitometric analysis of PrPC immuno-reactive
bands in control (–) or LPS-treated cells (+), normalized to the corresponding signal of α-Tubulin.
Data were then normalized to PrPC amounts in control cells. Data show that LPS addition significantly
increases PrPC expression levels in PrP-Tg-derived microglial cells. As expected, no PrPC reactive
band was observed in PrP-KO samples, confirming the specificity of the immunosignal. Values are
expressed as mean ± standard error of the mean (SEM), n = 3. Statistical analysis was based on
unpaired two-tailed Student’s t-test. ** p-value < 0.01. (B) PrPC regulates the production of cytokines by
primary murine microglial cells upon LPS treatment. Microglial cells (as in panel A) were maintained
in culture in the presence of LPS (500 ng/mL) for 24 h or 96 h. The amounts of selected cytokines
(IL-1β, IL-10, IFN-γ, IL-6 and TNF-α) released in the culture medium were quantified by a customized
enzyme-linked immunosorbent assay (ELISA) detection kit. The assays were performed in 96-well
filter plates by Multiplexed Luminex®-based immunoassay, as previously described [143], following
the manufacturer’s instructions, and analyzed in the BioPlex 200 instrument (BioRad). The table reports
the cytokine amounts (estimated from a standard curve using a fifth-order polynomial equation and
adjusted for the dilution factor), normalized to the total protein content (determined by a Lowry assay
kit (Sigma-Aldrich)) in the corresponding cell lysates and then subtracted for the values obtained in the
absence of LPS. Values are expressed as mean ± SEM, n = 5 (biological cultures for each genotype).
Statistical analysis was based on unpaired two-tailed Student’s t-test. * p-value < 0.05.
4. Concluding Remarks
As described in this review, microglia are likely to play a relevant role in prion neuropathology,
but—in light of the conflicting data accumulated over time—it is yet to be clearly understood if
microglia play as a beneficial actor in, or an enhancer of, prion-related neurodegeneration.
One of the most accredited pictures emerging from the above discussed reports envisages that—in
the first stages of the disease—microglial cells act as a suppressor of neurotoxicity induced by PrPSc
deposits by facilitating their removal and clearance and by secreting anti-inflammatory factors that
prevent neuronal loss. However, in an advanced stage of disease, microglia would no longer be able to
contrast the effects of prolonged PrPSc accumulation and neurotoxic signalling, which would rather
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elicit the switching of microglia to a sustained/chronic pro-inflammatory response, thus worsening
brain damage.
Taking this view, it also is worth considering that the depletion of functional PrPC in microglia and
microglia-neuron crosstalk may exacerbate the effects of microglia misregulation, thereby contributing
to disease progression. Also in this case, however, past literature and the here-presented original data
offer a panel of conflicting data, thus highlighting once more the need for a deeper understanding of
the physiological PrPC function in different cellular environments and signalling pathways.
It is our opinion that a unifying definition of microglia role in prion disease pathogenesis is crucial
for both getting major insights into the neurodegenerative processes and developing suited therapeutic
strategies. Particularly, a prompt stimulation of the anti-inflammatory properties of microglia in the
first stages of prion diseases may represent an optimal target to ameliorate disease progression and the
quality of life of patients.
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KO knock-out
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